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Objective:
 
 To compare the 12-month cost-effectiveness
of milnacipran in maintenance treatment of depression
to that of medical follow-up without antidepressant.
 
Method:
 
 A Markov model with transition probabilities
from a double blind clinical trial demonstrating the pro-
phylactic efficacy of milnacipran was used. Other pa-
rameters were obtained from published sources.
 
Results:
 
 Base-case incremental cost for preventive treat-
ment was 1,191 FF. It was reduced to 685 FF when us-
ing a 25% hospitalization rate in case of recurrence. Pa-
tients with a high initial response had extra cost of 191
FF and cost-utility was estimated to be 23,875 FF per
QALY gained. For those patients, using a 25% hospi-
talization rate in case of recurrence, costs were lower at
1,174 FF and preventive strategy was dominating.
 
Conclusion:
 
 Cost of maintenance therapy is partially bal-
anced by the gain from recurrence prevention. It should
be focused on patients with few residual symptoms or a
high probability of hospitalization in case of recurrence.
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In 1990, depressive disorders were the fourth
leading cause of disability and premature mortal-
ity worldwide, and projections for the years 1990–
2020 predict depression to be second only to car-
dio-ischemic diseases [1]. 1990 world estimates of
the incidence of depression suggest that there were
almost 110 million depressive episodes, corre-
sponding to an incidence of about 2% and a
yearly prevalence of about 1.3% [2]. National ep-
idemiological data show a yearly prevalence for
depression in France of 4.5% to 6% [3,4] and in
the United States of 4.9% [5]. In the World Health
Organization multicenter study [6], 25% of pa-
tients had a loss of social functioning for more
than 50% of the 10-year follow-up period. Pa-
tients remained ill for about 3 years of the 10-year
follow-up period. 10% had an episode lasting
over 2 years during follow-up, 11% of all patients
completed suicide, and 14% made unsuccessful
suicide attempts during the same period.
The 1990 cost of depression for the United
States was estimated at $43.7 billion (US) per year
[7]; only 28% of these costs (12.4 billion) was at-
tributable to direct medical costs while 55% was
attributable to morbidity costs (23.8 billion) in-
cluding absenteeism from work and reduced pro-
ductivity during depressive episodes. In France, di-
rect costs have been estimated at about 8.5 billion
 
French Francs (FF; 1 USD 
 

 
 6 FF) by Le Pen [8]
from a 10-year French survey on medical con-
sumption based on self-reported diagnoses. Hos-
pitalization costs contributed to 61% of the direct
cost in US estimates [7]. Therefore, interest in the
assessment of relapse-preventive treatment has led
to several long-term clinical trials during the last
20 years [9] and the efficacy of continuation treat-
ment has been substantiated. To fully prevent a re-
lapse when acute response has occurred, recom-
mendations are to continue at the same dosage for
4 to 9 months after a return to an euthymic state
[10]. The results of a 3-year study supported the
value of long term treatment with tricyclic antide-
pressants (TCA) in patients with recurrent depres-
sion; there was roughly a 0% recurrence rate for
imipramine compared with 80% for placebo.
Maintenance medication is strongly recommended
for patients who have had 3 episodes of major de-
pression but should also be considered for patients
who have experienced 2 episodes within a 5-year pe-
riod [11,12]. Such long-term treatment of depression
would benefit from an economic assessment to com-
pare directs costs to the costs engendered by succes-
sive depressive episodes. Milnacipran is an antide-
pressant that inhibits the re-uptake of both serotonin
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and noradrenalin. Its efficacy in the prevention of de-
pressive recurrences was demonstrated in a double-
blind randomized placebo-controlled trial [13]. The
clinical efficacy may impact cost-effectiveness, since
the higher costs of maintenance treatment may be, at
least in part, offset by savings in other costs (costs for
treatment of a new episode, including hospitaliza-
tion). The present study used a modeling technique
to compare the cost-effectiveness of milnacipran in
long-term maintenance treatment of depression (pre-
ventive strategy) with that of a medical follow-up
treating new episodes when diagnosed (episodic
strategy).
 
Methods
 
A cost-utility analysis introducing burden on the
patient due to long-term treatment was used in
this economic assessment. Economic assessment
was performed from the perspective of the French
Sickness Fund (Sécurité Sociale) and restricted to
direct medical costs. Indirect costs could not be es-
timated because no information was available on
the loss of productivity during a depressive epi-
sode in France. Direct costs of treatment included
psychiatrist fees, cost of drugs, and cost of recur-
rences (drugs, fees and hospitalizations) based on
the usual reference documents available in France:
• Nomenclature Générales des Actes Profession-
nels 1999 [14] (NGAP): This document is pub-
lished by the Union des Caisses Nationales de
Sécurité Sociale (UCANSS), grouping the dif-
ferent Sickness Funds in France. In this docu-
ment, medical procedures are described and a
coefficient is provided for each. This coeffi-
cient is multiplied by a key-letter depending on
the speciality of the professional (physician,
nurse, anaesthesist, etc.) to determine the cor-
responding fee. The values in Francs of the
key-letter are usually updated each year by the
Government;
• Tarif InterMinistériel des Prestations Sanitaires
1999 [15] (TIPS): This document, also pub-
lished by UCANSS, provides the tariff that is
taken into account for reimbursement of medi-
cal devices. These tariffs may or may not be
the real prices of device;
• Dictionnaire VIDAL 1999 [16]: In this document,
used by French physicians, prices of drugs and
some currently used devices are listed. Pharma-
ceutical prices (if they are reimbursed by Public
Health Funds) are fixed by the Public Health Au-
thorities.
• Cost of hospitalization was estimated from the
daily price at the Hospital Sainte Anne (2,730
FF per day) in Paris multiplied by the average
length of stay for depression of 13 days.
This economic estimation was performed using a
Markov model, to compare the continuous treat-
ment with milnacipran (preventive strategy) versus
follow-up with no preventive treatment (episodic
strategy). The results of a 12-month double-blind
trial assessing the efficacy of milnacipran compared
to placebo in the prevention of depression recur-
rences were used.
Patients had at least 1 previous episode, the
most recent occurring between 2.5 years and 6
months before the index episode. To ensure recov-
ery, the double blind randomized phase was pre-
ceded by a 6-month open trial of milnacipran to
achieve remission and recovery. Included in the
maintenance phase were 214 patients who had
Hamilton Depression Rating Scale-21 (HDRS
 
21
 
)
items scores less than 8. The observed recurrence
rate was higher in the placebo group (23.6% ver-
sus 16.3% in the milnacipran group (
 
P
 
 
 

 
 0.05)) as
was the dropout rate (24.6% in the placebo group
versus 18.3% in the milnacipran group, 
 
P
 
 
 

 
 0.05)
[13]. Moreover, clinical benefit was higher for pa-
tients without residual symptoms at randomiza-
tion (defined by an HDRS
 
21
 
 score 
 

 
5) with a re-
currence rate of 8.0% with milnacipran versus
25.0% with placebo (
 
P
 
 
 

 
 0.022).
 
Description of the Model
 
A Markov model [17] represented the evolution of
depressive recurrence. The structure of this model
was based on the characteristics of the clinical trial,
with time periods of 8 weeks (called cycles) corre-
sponding to the follow-up schedule in the trial.
At initiation, the patients in remission (HDRS
 
21
 
score 
 

 
8 after 6 months of treatment with mil-
nacipran for the index-episode) were either main-
tained with milnacipran (preventive) or simply
asked to visit their psychiatrist every two months
(episodic). At the end of each cycle, patients were
assessed for recurrence, a health status transition,
based on the transition probabilities determined in
the model. The transition probabilities were esti-
mated both from the clinical data of the trial and
also from published epidemiological data and ex-
pert opinion; the probabilities varied according to
the different health states and time elapsed in
these states.
Four health states were defined:
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• Remission plus a 2-month follow-up visit with
a specialist: no symptoms; maintenance treat-
ment and 2-month follow-up visit to a psychia-
trist versus no pharmacological treatment with
2-month follow-up visit to a psychiatrist.
• Recurrence: occurrence of a new depressive ep-
isode with a specific treatment.
• Remission without follow-up by a specialist:
patients without depression who failed to at-
tend the 2-month visit to the psychiatrist for
any reason and who discontinued maintenance
treatment with milnacipran in the preventive
group.
• Death by suicide.
For each health state, medical resources were
estimated and a standard cost approach was per-
formed. Markov states and transitions used in the
model are presented in Figure 1.
The transition probabilities were estimated us-
ing an actuarial life-table method. Estimates from
the literature were converted into transition prob-
abilities according to Miller and Homan’s recom-
mendations [18].
For recurrence, a former model developed by the
authors and based on literature review validated by a
Figure 1 Description of the Markov model
health state transition diagram
Table 1 Estimated probabilities used in the model according to parameter and source
 
s
Parameters Sources Rates (at the end of the period)
Recurrence rates Actuarial life table analysis
Clinical Trial Period Preventive strategy Episodic strategy
Month 1–2 0.0392 0.0748
Month 3–4 0.0737 0.0324
Month 5–6 0.0357 0.0848
Month 7–8 0.0267 0.0423
Month 9–10 0.0144 0.0451
Month 11–12 0 0.0225
Withdrawal rates Actuarial life table analysis
Clinical Trial Period Preventive strategy Episodic strategy
Month 1–2 0.0392 0.0566
Month 3–4 0.0216 0.0741
Month 5–6 0.0702 0.0848
Month 7–8 0.0779 0.0284
Month 9–10 0 0.0153
Month 11–12 0.02 0.0444
Suicide rates INSEE [23]
Avery [24] During recurrence: 0.5% per year
Black [25] No recurrence: General population rate (
 

 
20 years)
Fawcett [26] 0.02% per year
Tollefson [27]
Not cured after six
months of treatment
of recurrence episode
Coryell [22] Month 7–8: 0.48
Month 9–10: 0.73
Month 11–12: 0.77
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panel of experts [19] was used. This model assumes
a 6-month treatment of acute episodes according to
published expert recommendations [10], and corre-
sponds to 3 cycles of this current Markov model.
The episodic treatment included 8 weeks of initial
acute treatment followed by 16 weeks of continua-
tion treatment. With failure in ambulatory treatment
(first-line treatment followed by a switch to second
line treatment), patients could either receive aug-
mented treatment, be briefly hospitalized for a medi-
cal check-up, or fully hospitalized for treatment.
Since hospitalization is the main cost driver in de-
pression in France [20], a literature search revealed
that annual rates of hospitalization varied between
2.4% and 48% [21–23]; therefore, a median rate of
12% was chosen for the base case analysis.
Final response rates to recurrence treatment
were based on the literature. Experts recom-
mended a 6-month treatment for an acute episode
although some patients were still depressed after
this period. From the review of literature, it ap-
peared that most publications provided at best an-
nual rates of remission [24]. The most detailed in-
formation was given by Keller et al. [25] and
Coryell et al. [26]. Both publications referred to
the same study (the NIMH Collaborative Study on
the Psychobiology of Depression) and the esti-
mates for this model were based on the latter pub-
lication which included a larger population.
Two different rates were used for remitted (or
withdrawn) and for depressed patients (during a
recurrence episode) who committed suicide. The
annual remission rate was that of the French adult
population (0.02%) [27]. For currently depressed
patients, follow-up studies and databases of clini-
cal trials yielded an annual rate of suicide between
0.5% and 1.4% [28–31]. Three suicides occurred
during the open-label phase of the clinical trial,
yielding an annual rate of 0.6%. Lifetime rate esti-
mates of suicide have recently been lowered from
15% to 3.5–6% in recent analyses [32,33], and
we chose the lowest value (0.5%) as a conserva-
tive estimate. Sources and parameters used are
summarized in Table 1.
 
Economic Data
 
Medical resources used in the different health
states included:
• Visits during remission period: bimonthly.
• Maintenance treatment with milnacipran using
a daily dose of 50 mg bid.
• Recurrence costs were calculated using a model
for acute treatment that compared different
psychotropic drugs [19]. Mean costs were used
according to various assumptions about the
rate of hospitalization.
No direct medical costs were attributed to suicide
and remission without follow-up. (See Table 2.)
 
Utility Estimates
 
The health state utility measurement reflects pa-
tient preference or desirability for a particular
health state. This parameter is measured on a scale
from 0 to 1, with 0 representing death and 1 rep-
resenting perfect health. Several different scaling
methods are available for obtaining direct or indi-
rect rating of this parameter from the patients or
from their proxies for use in decision analytic
models. QALY was calculated for each outcome
in the model by multiplying the utility weight for
each health state by the number of months spent
in that health state.
(1) 
The present study used coefficients published by
Anton and Revicki [34]. The resulting utility esti-
mates are presented in Table 3.
U QALY tiUi
i 0=
i 12=
∑= =
 
Table 2
 
Recurrence costs according to the rate of 
hospitalization (for 6 months
 
)
Estimated
hospitalization
rate
Mean cost of
recurrent episode
Percentage of cost
accounting for hospitalization
2.4% [31] 4,402 FF 27.2%
12% median 9,266 FF 67.4%
25.2% [13] 16,223 FF 81.2%
 
Table 3
 
Health states and associated utility estimates [34]
 
Remission
with follow-up
Remission
without follow-up
Recurrence
first 2 months
Recurrence
months 3 & 4
Recurrence
months 5 & 6
Preventive strategy 0.875 0.895 0.306 0.725 0.795
Episodic strategy 0.895 0.895 0.306 0.725 0.795
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Results
 
Base Case Analysis
 
Economic results obtained in the model for our
baseline analysis (hospitalization rate 12%) are
presented in Table 4.
Results show an extra cost for the maintenance
strategy of 1,191 FF. The costs of the maintenance
anti-depressant therapy are only partially offset by
the benefit coming from a lower level of recurrence.
 
Sensitivity Analysis
 
The sensitivity analysis for total cost using differ-
ent assumptions for hospitalization rates is shown
in Table 5.
With a lower rate of hospitalization, the cost
of maintenance therapy was higher (
 

 
1,546 FF),
whereas with a higher rate of hospitalization (cor-
responding to the rate observed during the first
phase of the clinical trial), this extra cost was only
 

 
685 FF.
We also performed an analysis for the sub-group
of patients with an HDRS
 
21
 
 lower than 5 at the be-
ginning of the maintenance phase. These results ac-
cording to the different hospitalization rates are
presented in the Table 6.
At this higher level of efficacy for the mainte-
nance strategy, extra costs were lower than in the
core analysis. Difference in the baseline analysis
was only 191 FF. With the 2.4% rate for hospital-
ization, extra cost was 1,137 FF but there was an
economic benefit (
 

 
1,174 FF) at the 25% hospi-
talization rate. Utility estimates were also calcu-
lated and results expressed in QALY per patient
are presented in Table 7.
For the whole population, the difference was in
favor of the episodic strategy. The benefit in terms
of QALY due to recurrence episodes avoided did
not offset the decrease of quality of life associated
with preventive treatment.
For the group of patients with a HDRS
 
21
 
 
 

 
 5 at
inclusion, there is a benefit in the utility estimate
of 0.008. However, these differences cannot be
considered clinically significant [34]. Cost-utility
ratios can then be calculated for the 2.4 and 12%
hospitalization rates.
• Hospitalization rate 12%: 23,875 FF per
QALY gained;
• Hospitalization rate 2.4%: 142,125 FF per
QALY gained.
Lastly, in the case of hospitalization rate of 25%,
preventive therapy demonstrated lower costs and
better utility estimates than the episodic treatment
strategy.
 
Discussion
 
This study examined the cost-effectiveness of a
preventive treatment strategy for depression com-
pared to an episodic strategy (no prevention). At first
glance, our results seem to be less favorable than
other model findings for preventive strategy [35–
38]. However, the validity of the modeling tool in-
herently depends on the incorporated clinical data
and assumptions used. The first parameter to be
estimated is the differential efficacy between the
compared strategies. There have been numerous
placebo-controlled trials evaluating maintenance
pharmacotherapy in recurrent depressive disorder
but only a few of them had a design similar to the
present study [39]. Studies with similar designs are
crucial for modeling and their qualities directly affect
 
Table 4
 
Economic results: breakdown of mean annual cost 
per patient (FF)
 
Type of costs
Episodic
strategy
Preventive
strategy Difference
Recurrence (fees, drugs,
hospital) 2,845 FF 2,170 FF
 

 
675 FF
Maintenance
Physician fees 922 FF 1,026 FF
 

 
104 FF
Drugs for prevention
 

 
1,762 FF
 

 
1,762 FF
Total costs 3,767 FF 4,958 FF
 

 
1,191 FF
Hospitalization as %
of total costs 50.9% 29.5%
 
Table 5
 
Sensitivity analysis for the various hospitalization rates
 
Hospitalization rate: 2.4% Hospitalization rate: 25%
Costs Episodic strategy Preventive strategy Episodic strategy Preventive strategy
Recurrence 1,351 FF 1,031 FF 4,980 FF 3,799 FF
Maintenance 922 FF 2,788 FF 922 FF 2,788 FF
Total 2,273 FF 3,819 FF 5,902 FF 6,587 FF
Hospitalization as
% of total cost 16.2% 7.3% 68.5% 46.8%
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the validity of such a model. For instance, study pop-
ulations should ideally include patients at high risk
for recurrence. This was not the case in some studies
(e.g., [40]), and this information is missing in other
reports [41,42]. Patients ideally should be studied af-
ter a period of remission of 4 months in order to dis-
tinguish relapse from recurrence: shorter remission
periods bias the results in favor of the active product
because patients included in the placebo group are
withdrawn from active treatment too early [10].
Another possibility is the role of a withdrawal re-
action [43]. Maintenance studies that do not include
a defined symptom-free interval may favor the active
drug (e.g., [40,44,45]). Furthermore, the real mainte-
nance phase is shortened if one must subtract a con-
tinuation period of 4 months of the total follow-up
period (12 months in most cases). These method-
ological variations result in a wide range of recur-
rence rates for the placebo group from 20% to 80%.
Therefore, some economic models of maintenance
therapies are still speculative because no controlled
study was available to substantiate the clinical hy-
potheses (e.g., [37]) that rely on relapse prevention
data rather than maintenance data [46,47].
Results of the present model are derived from a
clinical controlled study on a highly recurrent sample,
which required a 4-month remission state before in-
clusion. Results showed a greater benefit for patients
with few residual symptoms (HDRS
 
21
 
 
 

 
 5). This is in
accordance with several studies where results were
stratified according to the HDRS at inclusion [48–
51]. The efficacy directly influences utility estimates
since the cost of maintenance strategy might be out-
weighed by the gain due to avoided recurrences. Be-
sides efficacy, the cost of a depressive recurrence is
the second most important parameter in such mod-
els. It is driven by the cost of hospitalization and this
directly depends on the rate and length of stay of hos-
pitalization. For example, the proportion of cost due
to hospitalization has been estimated to be as high as
86.2% [38] or 61% [36]. These estimates are higher
than our highest estimates and even in that case
maintenance strategy is cost-effective compared to no
maintenance. Therefore, the rate of hospitalization in
case of a new episode is of utmost importance for an
economic assessment of maintenance therapy in de-
pression. No national statistics on hospitalization for
depressive episodes are available in France. A rough
assessment by one of the authors (RMD), based on
different surveys made in the public and the private
sectors, gives a 5% rate per year (unpublished re-
sults). But risk of hospitalization is probably not
evenly distributed. A clinical trial made in primary
care has shown a rate of 2.5% per year [31]. On the
contrary, a sample of highly recurrent depressed pa-
tients included in a prospective study has shown a
much higher rate of hospitalization—about 40% per
year [33]. Maintenance treatments may be more cost-
effective for patients at high risk of rehospitalization.
To conclude, the developed Markov model dem-
onstrated an acceptable cost-utility ratio for recur-
rence prevention with milnacipran compared with
that estimated in France for hemodialysis [52]
greater than 400,000 FF per year. The cost of main-
tenance therapy is partially balanced by the gain
from recurrence prevention. Prevention of recur-
rence may best be focused on patients with few re-
sidual symptoms in remission and a high probability
of rehospitalization in case of recurrence.
 
This work was supported by an unrestricted grant from
Pierre Fabre Médicaments, Castres, France, which manu-
factures milnacipran.
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